Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | BCHE | P06276 | 3/20 | 0.48 |
| ▸ | ACHE | P22303 | 3/20 | 0.48 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
| ▸ | UBE2M | P61081 | 5/20 | 0.46 |
| ▸ | DCUN1D1 | Q96GG9 | 5/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4712779 | 0.91 | DRD2 (0.47) | CCR5DRD2KCNH2BCHEACHE | |
| SCHEMBL3542065 | 0.88 | KCNH2 (0.56) | CCR5DRD2KCNH2BCHEACHE | |
| SCHEMBL3532809 | 0.86 | DRD2 (0.49) | CCR5DRD2KCNH2BCHEACHE | |
| SCHEMBL3539247 | 0.85 | CCR5 (0.58) | CCR5DRD2KCNH2UBE2MDCUN1D1 | |
| SCHEMBL5969537 | 0.78 | CCR5 (0.49) | CCR5DRD2KCNH2UBE2MDCUN1D1 | |
| SCHEMBL13800059 | 0.76 | OPRM1 (0.49) | DRD2KCNH2ACHEMEN1RAB9A | |
| SCHEMBL5969609 | 0.75 | CCR5 (0.47) | CCR5KCNH2UBE2MDCUN1D1CYP3A4 | |
| Bamipine SCHEMBL29626 | 0.75 | KCNH2 (0.66) | CCR5DRD2KCNH2MEN1RAB9A | |
| SCHEMBL4306235 | 0.75 | MEN1 (0.53) | CCR5MEN1KMT2A | |
| SCHEMBL4306762 | 0.75 | SLC6A2 (0.55) | DCUN1D1CYP3A4SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9266841-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2016-02-23 | — | — | US | disclosed |
| US-8871775-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2014-10-28 | — | — | US | disclosed |
| US-20120172378-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-07-05 | — | — | US | disclosed |
| US-7470694-B2 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM, PLC (GB) | 2008-12-30 | — | — | US | disclosed |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | SMITHKLINE BEECHAM PLC | 2007-07-05 | — | — | US | disclosed |
| US-7153861-B2 | For therapy of atheroscelerosis | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-12-26 | — | — | US | disclosed |
| EP-1263740-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SmithKline Beecham plc (GB) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001060805-A1 | PYRIMIDINE-4-ONE DERIVATIVES AS LDL-PLA2 INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172378-A1 | NOVEL COMPOUNDS | PLA2G7, ALOX15B, PLA2G1B | CCR5 1478/4885DRD2 4421/4885KCNH2 4005/4885 |
| US-20070155762-A1 | Treating atherosclerosis by administering 1-(N-(2-(diethylamino)ethyl)-N-(4-(4-trifluoromethylphenyl)benzyl)aminocarbonylmethyl)-2-(4-fluorobenzyl)thio-5,6-trimethylenepyrimidin-4-one or a salt; coadministering an anticholesterol agent; inhibitor of platlet activating factor acetylhydrolase | PLAT, PLA2G7, LYPLAL1 | CCR5 2440/4885DRD2 4806/4885KCNH2 4763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.